Madrigal Pharmaceuticals Inc [MDGL] Investment Appeal on the Rise

Madrigal Pharmaceuticals Inc’s filing revealed that its Director CRAVES FRED B unloaded Company’s shares for reported $2.56 million on Mar 12 ’25. In the deal valued at $331.84 per share,7,728 shares were sold. As a result of this transaction, CRAVES FRED B now holds 350,076 shares worth roughly $99.76 million.

Then, CRAVES FRED B sold 7,742 shares, generating $2,518,053 in total proceeds. Upon selling the shares at $325.25, the Director now owns 350,076 shares.

Before that, FRED CRAVES bought 7,742 shares. Madrigal Pharmaceuticals Inc shares valued at $2,518,054 were divested by the Director at a price of $325.25 per share.

B. Riley Securities upgraded its Madrigal Pharmaceuticals Inc [MDGL] rating to a Buy from a a Neutral in a research note published on February 28, 2025; the price target was increased to $422 from $236. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late February has reiterated a ‘”a Buy”‘ rating for it. Cantor Fitzgerald began covering MDGL with “Neutral” recommendation on June 28, 2024. Wolfe Research started covering the stock on June 11, 2024. It rated MDGL as “an Outperform”.

Price Performance Review of MDGL

On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 0.70% to $284.98. Over the last five days, the stock has lost -0.03%. Madrigal Pharmaceuticals Inc shares have risen nearly 6.42% since the year began. Nevertheless, the stocks have fallen -7.64% over the past one year. While a 52-week high of $377.46 was reached on 02/26/25, a 52-week low of $200.63 was recorded on 05/27/25.

Levels Of Support And Resistance For MDGL Stock

The 24-hour chart illustrates a support level at 279.32, which if violated will result in even more drops to 273.66. On the upside, there is a resistance level at 290.32. A further resistance level may holdings at 295.66.

How much short interest is there in Madrigal Pharmaceuticals Inc?

A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on 2025-05-30, dropping by -0.22 million shares to a total of 3.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 4.1 million shares. There was a decline of -5.64%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on April 22, 2024 when BofA Securities began covering the stock and recommended ‘”an Underperform”‘ rating along with a $150 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.